Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Black and African American Adults: Results From 3 Randomized, Placebo-Controlled Clinical Trials
Headache
P9 - Poster Session 9 (5:30 PM-6:30 PM)
2-009

Rimegepant is an orally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute and preventive treatment of migraine. Studies showing the effects of medications for the acute treatment of migraine in Black and African American individuals are limited. It is unclear whether the acute treatment effects of rimegepant in under-represented populations are similar to those in the overall migraine population.

Compare the efficacy of rimegepant 75 mg with placebo in the acute treatment of migraine in Black and African American adults.

Post hoc subgroup analyses were conducted using pooled data from 3 double-blind, randomized, placebo-controlled studies of rimegepant 75 mg for acute treatment in Black and African American adults aged ≥18 years with a ≥1-year history of migraine. The co-primary efficacy endpoints were pain freedom and most bothersome symptom (MBS) freedom at 2 hours postdose. Treatment groups were compared using nominal p-values.

Of the 3551 efficacy-evaluable participants, 19.6% were Black or African American (N=696, rimegepant n=365, placebo n=331). The demographics of Black and African American participants were comparable to those seen in the overall study population, but there were fewer women (79% vs 83%) and the use of preventive medication was lower (14% vs 22%). Response rates were higher on rimegepant than placebo for 2-hour pain freedom (24.4% vs 18.2%, p=0.0473) and MBS freedom (43.1% vs 35.5%, p=0.0413). Outcomes on the coprimary endpoints in the overall population were similar for pain freedom at 2 hours postdose (20.1% vs 12.2%, p<0.0001) and freedom from the MBS at 2 hours postdose (36.4% vs 26.6%, p<0.0001). Treated participants reported no serious adverse events.

Rimegepant 75 mg showed benefits for the acute treatment of migraine in Black and African American adults that were similar to those observed in the overall trial population.

Authors/Disclosures
Larry Charleston, IV, MD, MSc, FAHS (Michigan State University College of Human Medicine)
PRESENTER
Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/AbbVie. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven Biopharmaceuticals. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LinPharma. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Haleon. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Charleston has a non-compensated relationship as a Associate Editor with Headache Journal: The Journal of Head and Face Pain that is relevant to AAN interests or activities. Dr. Charleston has a non-compensated relationship as a Board Member at Large with Alliance for Headache Disorders Advocacy that is relevant to AAN interests or activities. Dr. Charleston has a non-compensated relationship as a Board Member with Clinical Neurological Society of America that is relevant to AAN interests or activities.
Cynthia Emilie Armand, MD (Montefiore Medical Headache Center) Dr. Armand has received personal compensation in the range of $0-$499 for serving as a Consultant for Abbvie. Dr. Armand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TEVA. Dr. Armand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Spire Learning. Dr. Armand has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology.
Wendell R. Helveston, MD (Hattiesburg Clinic) Dr. Helveston has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Helveston has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Helveston has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Dr. Helveston has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for BMS Pharmaceuticals. Dr. Helveston has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Helveston has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Helveston has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Helveston has stock in Biogen. An immediate family member of Dr. Helveston has received personal compensation in the range of $500-$4,999 for serving as a Spokesperson with Lundbeck.
Teshamae Monteith, MD, FAAN (University of Miami) Dr. Monteith has received personal compensation in the range of $0-$499 for serving as a Consultant for Abbvie. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LinPharma. Dr. Monteith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HMP Global . Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for American Headache Society . Dr. Monteith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for e-Neura. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Monteith has received personal compensation in the range of $0-$499 for serving as a Consultant for Merz. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alder. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alder. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva . Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . The institution of Dr. Monteith has received research support from AbbVie. The institution of Dr. Monteith has received research support from Amgen. The institution of Dr. Monteith has received research support from Teva. The institution of Dr. Monteith has received research support from Electrocore. The institution of Dr. Monteith has received research support from Novartis . The institution of Dr. Monteith has received research support from Amgen. The institution of Dr. Monteith has received research support from lilly. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Education with Medscape. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Education with Massachusetts Medical Society . Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Education with Academic CME. Dr. Monteith has received personal compensation in the range of $10,000-$49,999 for serving as a Education with Rockpointe. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Neuodiem. Dr. Monteith has a non-compensated relationship as a President Elect with Florida Society of Neurology that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Editorial Board with American Migraine Foundation that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Board Member with International Headache Society that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Pfizer that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Abbvie that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Theranica that is relevant to AAN interests or activities.
Hope O'Brien, MD, FAAN, MBA (Headache Center of Hope) The institution of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. The institution of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GatherED . The institution of Dr. O'Brien has received personal compensation in the range of $0-$499 for serving as a Consultant for Guidepoint. The institution of Dr. O'Brien has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. The institution of Dr. O'Brien has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. The institution of Dr. O'Brien has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. An immediate family member of Dr. O'Brien has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Astra Zenica. The institution of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven. The institution of Dr. O'Brien has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. O'Brien has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lilly. Dr. O'Brien has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Ms. Medicine. The institution of Dr. O'Brien has received research support from Abbvie. The institution of Dr. O'Brien has received research support from Eli Lilly. Dr. O'Brien has received publishing royalties from a publication relating to health care. Dr. O'Brien has a non-compensated relationship as a Accreditation Council Member with UCNS that is relevant to AAN interests or activities.
Robert Croop, MD Dr. Croop has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Dr. Croop has received personal compensation for serving as an employee of Pfizer Inc.. Dr. Croop has stock in Biohaven Pharmaceutical Holding Co Ltd. Dr. Croop has stock in Biohaven Ltd.. Dr. Croop has received intellectual property interests from a discovery or technology relating to health care.
Alexandra Thiry Alexandra Thiry has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Alexandra Thiry has received stock or an ownership interest from Biohaven Pharmaceuticals.
Beth Morris Beth Morris has received personal compensation for serving as an employee of Biohaven Pharmaceuticals Inc. Beth Morris has received stock or an ownership interest from Biohaven Pharmaceuticals Inc.
Micaela Forshaw Micaela Forshaw has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Micaela Forshaw has received stock or an ownership interest from Biohaven Pharmaceuticals.
Chandra Coleman Abbott, PhD (Pfizer, Inc.) Dr. Abbott has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Dr. Abbott has stock in Biohaven Pharmaceuticals, Inc..